Group  ||| S:0 E:6 ||| NNP
I  ||| S:6 E:8 ||| NNP
metabotropic  ||| S:8 E:21 ||| FW
glutamate  ||| S:21 E:31 ||| FW
receptor  ||| S:31 E:40 ||| FW
agonist  ||| S:40 E:48 ||| FW
DHPG  ||| S:48 E:53 ||| FW
modulates  ||| S:53 E:63 ||| FW
Kir4.1  ||| S:63 E:70 ||| FW
protein  ||| S:70 E:78 ||| NN
and  ||| S:78 E:82 ||| CC
mRNA  ||| S:82 E:87 ||| JJ
in  ||| S:87 E:90 ||| IN
cultured  ||| S:90 E:99 ||| FW
rat  ||| S:99 E:103 ||| FW
retinal  ||| S:103 E:111 ||| FW
Müller  ||| S:111 E:118 ||| FW
cells  ||| S:118 E:124 ||| FW
Müller  ||| S:124 E:131 ||| FW
cell  ||| S:131 E:136 ||| FW
gliosis  ||| S:136 E:144 ||| FW
is  ||| S:144 E:147 ||| VBZ
a  ||| S:147 E:149 ||| DT
general  ||| S:149 E:157 ||| JJ
response  ||| S:157 E:166 ||| NN
in  ||| S:166 E:169 ||| IN
a  ||| S:169 E:171 ||| DT
variety  ||| S:171 E:179 ||| NN
of  ||| S:179 E:182 ||| IN
pathological  ||| S:182 E:195 ||| JJ
alternations  ||| S:195 E:208 ||| NN
of  ||| S:208 E:211 ||| IN
the  ||| S:211 E:215 ||| DT
retina ||| S:215 E:221 ||| NN
,  ||| S:221 E:223 ||| ,
which  ||| S:223 E:229 ||| WDT
is  ||| S:229 E:232 ||| VBZ
characterized  ||| S:232 E:246 ||| VBN
by  ||| S:246 E:249 ||| IN
the  ||| S:249 E:253 ||| DT
upregulated  ||| S:253 E:265 ||| JJ
expression  ||| S:265 E:276 ||| NN
of  ||| S:276 E:279 ||| IN
glial  ||| S:279 E:285 ||| FW
fibrillary  ||| S:285 E:296 ||| FW
acidic  ||| S:296 E:303 ||| FW
protein  ||| S:303 E:311 ||| FW
( ||| S:311 E:312 ||| -LRB-
GFAP ||| S:312 E:316 ||| NNP
)  ||| S:316 E:318 ||| -RRB-
and  ||| S:318 E:322 ||| CC
the  ||| S:322 E:326 ||| DT
downregulation  ||| S:326 E:341 ||| NN
of  ||| S:341 E:344 ||| IN
membrane  ||| S:344 E:353 ||| JJ
K ||| S:353 E:354 ||| NNP
( ||| S:354 E:355 ||| -LRB-
+ ||| S:355 E:356 ||| NNP
)  ||| S:356 E:358 ||| -RRB-
conductance ||| S:358 E:369 ||| NN
.  ||| S:369 E:371 ||| .
We  ||| S:371 E:374 ||| PRP
have  ||| S:374 E:379 ||| VBP
demonstrated  ||| S:379 E:392 ||| VBN
that  ||| S:392 E:397 ||| IN
downregulation  ||| S:397 E:412 ||| NN
of  ||| S:412 E:415 ||| IN
Kir  ||| S:415 E:419 ||| NNP
K ||| S:419 E:420 ||| NNP
( ||| S:420 E:421 ||| -LRB-
+ ||| S:421 E:422 ||| NNP
)  ||| S:422 E:424 ||| -RRB-
currents  ||| S:424 E:433 ||| NN
in  ||| S:433 E:436 ||| IN
Müller  ||| S:436 E:443 ||| NNP
cells  ||| S:443 E:449 ||| NNS
in  ||| S:449 E:452 ||| IN
an  ||| S:452 E:455 ||| DT
experimental  ||| S:455 E:468 ||| JJ
glaucoma  ||| S:468 E:477 ||| JJ
model  ||| S:477 E:483 ||| NN
is  ||| S:483 E:486 ||| VBZ
due  ||| S:486 E:490 ||| JJ
to  ||| S:490 E:493 ||| TO
activation  ||| S:493 E:504 ||| VB
of  ||| S:504 E:507 ||| IN
group  ||| S:507 E:513 ||| NN
I  ||| S:513 E:515 ||| PRP
metabotropic  ||| S:515 E:528 ||| VBP
glutamate  ||| S:528 E:538 ||| JJ
receptor  ||| S:538 E:547 ||| NN
( ||| S:547 E:548 ||| -LRB-
mGluR  ||| S:548 E:554 ||| NNP
I ||| S:554 E:555 ||| NNP
)  ||| S:555 E:557 ||| -RRB-
by  ||| S:557 E:560 ||| IN
glutamate ||| S:560 E:569 ||| NN
,  ||| S:569 E:571 ||| ,
which  ||| S:571 E:577 ||| WDT
contributes  ||| S:577 E:589 ||| VBZ
to  ||| S:589 E:592 ||| TO
Müller  ||| S:592 E:599 ||| NNP
cell  ||| S:599 E:604 ||| NN
gliosis ||| S:604 E:611 ||| NN
.  ||| S:611 E:613 ||| .
Here ||| S:613 E:617 ||| RB
,  ||| S:617 E:619 ||| ,
whether  ||| S:619 E:627 ||| IN
and  ||| S:627 E:631 ||| CC
how  ||| S:631 E:635 ||| WRB
activation  ||| S:635 E:646 ||| NNS
of  ||| S:646 E:649 ||| IN
mGluR  ||| S:649 E:655 ||| JJ
I  ||| S:655 E:657 ||| PRP
modulate  ||| S:657 E:666 ||| VBP
membrane  ||| S:666 E:675 ||| RB
Kir4.1  ||| S:675 E:682 ||| CD
protein  ||| S:682 E:690 ||| NN
internalization  ||| S:690 E:706 ||| NNS
and  ||| S:706 E:710 ||| CC
Kir4.1  ||| S:710 E:717 ||| CD
mRNA  ||| S:717 E:722 ||| JJ
expression  ||| S:722 E:733 ||| NN
were  ||| S:733 E:738 ||| VBD
investigated  ||| S:738 E:751 ||| VBN
in  ||| S:751 E:754 ||| IN
purified  ||| S:754 E:763 ||| FW
cultured  ||| S:763 E:772 ||| FW
rat  ||| S:772 E:776 ||| FW
retinal  ||| S:776 E:784 ||| FW
Müller  ||| S:784 E:791 ||| FW
cells  ||| S:791 E:797 ||| FW
using  ||| S:797 E:803 ||| FW
immunocytochemistry ||| S:803 E:822 ||| FW
,  ||| S:822 E:824 ||| ,
Western  ||| S:824 E:832 ||| JJ
blot  ||| S:832 E:837 ||| NN
and  ||| S:837 E:841 ||| CC
real-time  ||| S:841 E:851 ||| JJ
PCR  ||| S:851 E:855 ||| NN
techniques ||| S:855 E:865 ||| NNS
.  ||| S:865 E:867 ||| .
DHPG  ||| S:867 E:872 ||| NNP
( ||| S:872 E:873 ||| -LRB-
10μM ||| S:873 E:877 ||| NNP
,  ||| S:877 E:879 ||| ,
a  ||| S:879 E:881 ||| DT
selective  ||| S:881 E:891 ||| JJ
mGluR  ||| S:891 E:897 ||| NN
I  ||| S:897 E:899 ||| PRP
agonist ||| S:899 E:906 ||| VBP
)  ||| S:906 E:908 ||| -RRB-
treatment  ||| S:908 E:918 ||| FW
induced  ||| S:918 E:926 ||| FW
Müller  ||| S:926 E:933 ||| FW
cell  ||| S:933 E:938 ||| FW
gliosis ||| S:938 E:945 ||| FW
,  ||| S:945 E:947 ||| ,
as  ||| S:947 E:950 ||| RB
evidenced  ||| S:950 E:960 ||| VBN
by  ||| S:960 E:963 ||| IN
enhanced  ||| S:963 E:972 ||| JJ
GFAP  ||| S:972 E:977 ||| NNP
expression ||| S:977 E:987 ||| NN
.  ||| S:987 E:989 ||| .
Although  ||| S:989 E:998 ||| IN
total  ||| S:998 E:1004 ||| JJ
Kir4.1  ||| S:1004 E:1011 ||| CD
proteins  ||| S:1011 E:1020 ||| NNS
extracted  ||| S:1020 E:1030 ||| VBN
from  ||| S:1030 E:1035 ||| IN
the  ||| S:1035 E:1039 ||| DT
DHPG-treated  ||| S:1039 E:1052 ||| JJ
cells  ||| S:1052 E:1058 ||| NNS
kept  ||| S:1058 E:1063 ||| VBD
unchanged ||| S:1063 E:1072 ||| JJ
,  ||| S:1072 E:1074 ||| ,
Kir4.1  ||| S:1074 E:1081 ||| CD
proteins  ||| S:1081 E:1090 ||| NNS
in  ||| S:1090 E:1093 ||| IN
the  ||| S:1093 E:1097 ||| DT
cell  ||| S:1097 E:1102 ||| NN
membrane  ||| S:1102 E:1111 ||| NN
compartment  ||| S:1111 E:1123 ||| NN
were  ||| S:1123 E:1128 ||| VBD
significantly  ||| S:1128 E:1142 ||| RB
decreased ||| S:1142 E:1151 ||| VBN
,  ||| S:1151 E:1153 ||| ,
which  ||| S:1153 E:1159 ||| WDT
was  ||| S:1159 E:1163 ||| VBD
prior  ||| S:1163 E:1169 ||| RB
to  ||| S:1169 E:1172 ||| TO
the  ||| S:1172 E:1176 ||| DT
change  ||| S:1176 E:1183 ||| NN
of  ||| S:1183 E:1186 ||| IN
GFAP  ||| S:1186 E:1191 ||| NNP
in  ||| S:1191 E:1194 ||| IN
time  ||| S:1194 E:1199 ||| NN
course ||| S:1199 E:1205 ||| NN
.  ||| S:1205 E:1207 ||| .
In  ||| S:1207 E:1210 ||| IN
addition ||| S:1210 E:1218 ||| NN
,  ||| S:1218 E:1220 ||| ,
DHPG  ||| S:1220 E:1225 ||| NNP
( ||| S:1225 E:1226 ||| -LRB-
10  ||| S:1226 E:1229 ||| CD
and  ||| S:1229 E:1233 ||| CC
100μM ||| S:1233 E:1238 ||| CD
)  ||| S:1238 E:1240 ||| -RRB-
treatment  ||| S:1240 E:1250 ||| NN
induced  ||| S:1250 E:1258 ||| VBD
a  ||| S:1258 E:1260 ||| DT
transient  ||| S:1260 E:1270 ||| JJ
decrease  ||| S:1270 E:1279 ||| NN
in  ||| S:1279 E:1282 ||| IN
Kir4.1  ||| S:1282 E:1289 ||| CD
mRNA  ||| S:1289 E:1294 ||| JJ
expression  ||| S:1294 E:1305 ||| NN
in  ||| S:1305 E:1308 ||| IN
the  ||| S:1308 E:1312 ||| DT
cells ||| S:1312 E:1317 ||| NNS
.  ||| S:1317 E:1319 ||| .
All  ||| S:1319 E:1323 ||| PDT
these  ||| S:1323 E:1329 ||| DT
results  ||| S:1329 E:1337 ||| NNS
suggest  ||| S:1337 E:1345 ||| VBP
that  ||| S:1345 E:1350 ||| DT
activation  ||| S:1350 E:1361 ||| NN
of  ||| S:1361 E:1364 ||| IN
mGluR  ||| S:1364 E:1370 ||| JJ
I  ||| S:1370 E:1372 ||| NN
by  ||| S:1372 E:1375 ||| IN
DHPG  ||| S:1375 E:1380 ||| NNP
may  ||| S:1380 E:1384 ||| MD
decrease  ||| S:1384 E:1393 ||| VB
the  ||| S:1393 E:1397 ||| DT
number  ||| S:1397 E:1404 ||| NN
of  ||| S:1404 E:1407 ||| IN
functional  ||| S:1407 E:1418 ||| FW
Kir4.1  ||| S:1418 E:1425 ||| FW
channels  ||| S:1425 E:1434 ||| FW
in  ||| S:1434 E:1437 ||| FW
purified  ||| S:1437 E:1446 ||| FW
cultured  ||| S:1446 E:1455 ||| FW
rat  ||| S:1455 E:1459 ||| FW
retinal  ||| S:1459 E:1467 ||| FW
Müller  ||| S:1467 E:1474 ||| FW
cells  ||| S:1474 E:1480 ||| NNS
through  ||| S:1480 E:1488 ||| IN
modulating  ||| S:1488 E:1499 ||| CD
Kir4.1  ||| S:1499 E:1506 ||| CD
protein  ||| S:1506 E:1514 ||| NN
and  ||| S:1514 E:1518 ||| CC
mRNA ||| S:1518 E:1522 ||| JJ
,  ||| S:1522 E:1524 ||| ,
thus  ||| S:1524 E:1529 ||| RB
contributing  ||| S:1529 E:1542 ||| VBG
to  ||| S:1542 E:1545 ||| TO
Müller  ||| S:1545 E:1552 ||| NNP
cell  ||| S:1552 E:1557 ||| NN
gliosis ||| S:1557 E:1564 ||| NN
.  ||| S:1564 E:1566 ||| .
